CTLA4 and atherosclerosis: As 18F-FDG PET is widely used to analyze monocyte/macrophage-driven vascular and systemic inflammation in atherosclerosis, these data indicate that the antibody-mediated inhibition of CTLA4 did not affect the monocyte/macrophage-driven inflammation [16,17].